Addition of Quetiapine in Obsessive Compulsive Disorder - Westenberg Study
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
Quetiapine (Seroquel ®), an atypical antipsychotic registered for use in schizophrenia, which
has a very low propensity of extrapyramidal and endocrine side-effects, has also been studied
as an adjunct in OCD. In an open trial, ten patients with OCD who had not responded to at
least three previous treatments with a SRI at maximum dose and duration were assigned to
receive quetiapine in addition to a SRI for 8 weeks. Given the efficacy of quetiapine in
treatment resistant patients, and given its rapid onset of action (4-6 weeks), it is
postulated that the combination of a low dose atypical antipsychotic and a standard dosage of
an SRI as a treatment for patients with OCD might increase the number of responders as well
as the effect size.
PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation
was changed to XR after consultation with FDA.